Oncolytics Biotech

Oncolytics Biotech CROIC

The Cash Return on Invested Capital (CROIC) of Oncolytics Biotech (ONCY) as of Nov 21, 2026 is 557.90 %. In the previous year, Cash Return on Invested Capital (CROIC) was -401.85 % — a change of -238.84% (higher).

CROIC

557.90 %

YoY

-238.84%

Last updated:

Cash Return on Invested Capital (CROIC) of Oncolytics Biotech is 2025 557.90 % . Cash Return on Invested Capital (CROIC) of Oncolytics Biotech was 2024 -401.85 % . It decreases by -238.84% higher compared to the previous year.

The Oncolytics Biotech CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-194.14 USD
Jan 1, 2019
-4,999.48 USD
Jan 1, 2020
-87.85 USD
Jan 1, 2021
-61.82 USD
Jan 1, 2022
-87.11 USD
Jan 1, 2023
-101.68 USD
Jan 1, 2024
-401.85 USD
Jan 1, 2025
557.90 USD
The Oncolytics Biotech CROIC history
YEARCROICYoY
557.90 %-238.84%
-401.85 %+295.21%
-101.68 %+16.73%
-87.11 %+40.91%
-61.82 %-29.63%
-87.85 %-98.24%
-4,999.48 %+2,475.19%
-194.14 %-12.77%
-222.57 %+127.50%
-97.83 %+72.72%
-56.64 %-54.72%
-125.10 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncolytics Biotech Stock analysis

What does Oncolytics Biotech do? Oncolytics Biotech Inc. develops pelareorep, an intravenously delivered immunotherapeutic agent targeting gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company generates revenue through research and development agreements, including a supply agreement with Roche Holding AG for atezolizumab, which is used in its sponsored studies. Oncolytics focuses on clinical-stage oncology treatments, leveraging partnerships to advance its pipeline without commercializing products yet. Roche Holding AG supplies atezolizumab under an agreement with Oncolytics, enabling the company to conduct studies on pelareorep in combination with immune checkpoint inhibitors. This collaboration supports Oncolytics' research efforts in oncology, particularly for GI tumor treatments and metastatic cancers. The company remains in the clinical development phase, with no current commercial products. Oncolytics Biotech Inc. operates as a clinical-stage biopharmaceutical company, concentrating on immunotherapeutic agents for specific cancer types. Its primary revenue stream comes from research partnerships, such as the Roche collaboration, rather than product sales. The company does not yet have commercialized treatments, relying instead on sponsored studies and development agreements to fund its operations. Oncolytics Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncolytics Biotech stock

Cash Return on Invested Capital (CROIC) of Oncolytics Biotech is 557.90 % in 2025.

Cash Return on Invested Capital (CROIC) of Oncolytics Biotech changed from -401.85 % to 557.90 %, representing a -238.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Oncolytics Biotech since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Oncolytics Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Oncolytics Biotech

All Key Metrics — Oncolytics Biotech